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Abstract Non-steroidalanti-inﬂammatorydrugs(NSAIDs)
represent a diverse class of drugs and are among the
most commonly used analgesics for arthritic pain
worldwide, though long-term use is associated with a
spectrum of adverse effects. The introduction of
cyclooxygenase-2-selective NSAIDs early in the last
decade offered an alternative to traditional NSAIDs with
similar efﬁcacy and improved gastrointestinal tolerability;
however, emerging concerns about cardiovascular safety
resulted in the withdrawal of two agents (rofecoxib and
valdecoxib) in the mid-2000s and, subsequently, in an
overall reduction in NSAID use. It is now understood
that all NSAIDs are associated with some varying degree
of gastrointestinal and cardiovascular risk. Guidelines
still recommend their use, but little is known of how
patients use these agents. While strategies and guidelines
aimed at reducing NSAID-associated complications exist,
there is a need for evidence-based algorithms combining
cardiovascular and gastrointestinal factors that can be
used to aid treatment decisions at an individual patient
level.
Keywords Anti-inﬂammatory agents, non-steroidal 
Cyclooxygenase-2 inhibitors  Comparative efﬁcacy 
Comparative safety
Introduction
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are
among the most commonly used drugs in the world [1, 2].
With demonstrated efﬁcacy in the management of pain [3],
they are a recommended therapy for the large population
who suffer from osteoarthritis (OA) [4–7] and rheumatoid
arthritis (RA) [8]. However, their chronic use is associated
with a well-recognized spectrum of side effects, in partic-
ular those involving the gastrointestinal system [9] and, as
highlighted by the relatively recent withdrawal of certain
cyclooxygenase (COX)-2-selective agents (rofecoxib and
valdecoxib), the cardiovascular system [10, 11].
There was subsequently a reduction in the prescribing of
all NSAIDs [12, 13], re-thinking about the value of clas-
sifying drugs on COX selectivity alone, and increasing
investigation into the relative toxicity proﬁles of NSAIDs.
At the end of this rather turbulent decade for NSAIDs, it
now seems timely to brieﬂy review their classiﬁcation,
recent epidemiology of use, and the comparative efﬁcacy
and toxicity of different NSAIDs, with a focus on the
gastrointestinal and cardiovascular risks that pose a major
concern in practice.
For the purposes of this review, the terms non-selective
(ns) and COX-2-selective will be used where appropri-
ate, whereas the generic term NSAID will refer to all
agents. Peer-reviewed, English-language articles were
identiﬁed for inclusion in this review through searches of
MEDLINE and selected on the basis of their relevance.
Search terms included: NSAIDs, COX-2, efﬁcacy, safety,
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Mechanism of action of NSAIDs
The principle of NSAID therapy dates back to the use of
willow bark more than 5,000 years ago for musculoskeletal
pain [14, 15]. The active ingredient of willow bark, salicin,
was isolated in 1828 and the industrial production of sali-
cylic acid underway by 1874 [14, 15]. Aspirin (acetylsal-
icylic acid) was developed in 1897 in an attempt to
improve palatability [14, 15]. Indomethacin and ibuprofen
were among the ﬁrst non-aspirin NSAIDs to be introduced
in 1964 and 1969, respectively [14, 15]. Subsequently,
many new classes of NSAIDs have followed, including
diclofenac in 1974 and naproxen in 1976 [14, 15].
NSAIDs are a diverse group of drugs with common
analgesic, anti-inﬂammatory, and anti-pyretic therapeutic
properties [16]. The action of NSAIDs was ﬁrst described
in 1971 when Vane and Piper demonstrated that NSAIDs
inhibit the biosynthesis of prostaglandins by preventing the
substrate arachidonic acid from binding to the COX
enzyme active site [17]. The COX enzyme was subse-
quently found to exist in two isoforms—COX-1 was
characterized in 1976, and the gene for the COX-2 isoen-
zyme was later discovered in 1991 [17]. COX-1 is con-
stitutively expressed and catalyzes the production of
prostaglandins that are involved in numerous physiological
functions, including maintenance of normal renal function
in the kidneys, mucosal protection in the gastrointestinal
tract, and pro-aggregatory thromboxane A2 in the platelets
[17, 18]. By contrast, COX-2 expression can be induced by
cytokines and other inﬂammatory mediators in a number of
tissues, including endothelial cells, and is believed to have
a role in the mediation of pain, inﬂammation, and fever
[16, 17]. There has been speculation on the existence of a
third isoform, COX-3, which would explain the mechanism
of action of acetaminophen, a poor inhibitor of COX-1 and
COX-2. Splice variants of COX-1 and COX-2 have
emerged that have been referred to as COX-3 but have
transpired to have little relevance in humans [19].
Classiﬁcation of NSAIDs
NSAIDs can be classiﬁed according to numerous charac-
teristics, including COX selectivity, and chemical and
pharmacological properties (Table 1). NSAIDs generally
have chemical similarity in that they are relatively lipid-
soluble, weak acids. There are, however, some clinically
relevant differences in pharmacokinetic properties [20].
NSAIDs generally have high bioavailability after oral
administration. As a result of their chemical properties,
they are well absorbed from the gastrointestinal tract and
hepatic clearance is low [20]. However, the rate of
absorption varies between NSAIDs, which can impact
upon the suitability of different NSAIDs for particular
indications [20]. NSAIDs can also be categorized by half-
life into two groups: those with a short half-life (\6 h) and
Table 1 Classiﬁcation of selected NSAIDs by COX-2 selectivity, chemical and pharmacokinetic properties [18, 111–115]
NSAID COX-2
selectivity
(SI)
Chemical
structure
Bioavailability
(%)
Half-
life
(h)
Volume of
distribution
Clearance Peak
(h)
Protein
binding
(%)
Renal
elimination
(%)
Clinical
dose
(mg/d)
a
Ibuprofen Non-selective
(1.05)
Propionic
acid
[80 2 0.15 L/kg 3.0–3.5 L/h 1–2 99 45–79 1,200–3,200
Diclofenac Non-selective
(1.97)
Acetic
acid
50–60 2 0.1–0.2 L/kg 21.0 L/h 2 [99 65 100–150
Naproxen
b Non-selective
(0.33)
Propionic
acid
95 12–17 0.16 L/kg 0.13 mL/min/kg 2–4 [99 95 500–1,000
Meloxicam Selective
([2.04)
Oxicam 89 15–20 10 L 0.4–0.5 L/h 4–5 99 50 7.5–15.0
Celecoxib Selective
(7.70)
Pyrazole NS 11 400 L 27.7 L/h 3 97 27 200
Ketoprofen Non-selective
(0.02)
Propionic
acid
90 2.1 0.1 L/kg 6.9 L/h B2 [99 80 200–300
Etoricoxib Selective
(105.40)
Bipyridine 100% 22 120 L 50 mL/min 1 92 75 60
SI COX-2-selectivity index (SI = ratio of COX-1 half maximal inhibitory concentration [IC50]/COX-2 IC50), COX-2 cyclooxygenase-2, NS not
speciﬁed, NSAID non-steroidal anti-inﬂammatory drug
a Standard clinical dose for OA
b Non-enteric coated
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123those with a long half-life (Table 1). This provides a guide
to dosing with short half-life NSAIDs (e.g., ibuprofen)
generally administered every 6–8 h and longer half-life
NSAIDs (e.g., naproxen and celecoxib) administered once
or twice daily [20–23]. Rapid absorption is a desirable
feature for patients using NSAIDs for immediate analgesic
relief, but may not always be most appropriate for patients
with chronic pain.
Epidemiology of NSAID prescribing
NSAIDs are among the most commonly used drugs
worldwide, used by more than 30 million people every day
[2]. More than 111 million prescriptions are written for
NSAIDs in the USA annually, and they account for
approximately 60% of the USA over-the-counter (OTC)
analgesic market [1].
The most commonly used NSAIDs are diclofenac and
ibuprofen, which account for almost 40% of global NSAID
sales for OA [24] (Fig. 1). Excluding OTC use, ibuprofen
and naproxen are the most commonly prescribed NSAIDs
in the USA, while diclofenac prescription is more common
in the UK [24]. Reasons for regional variation may not just
relate to drug properties but may also include which
NSAID was ﬁrst to market in a particular region.
The introduction of COX-2-selective agents with
improved gastrointestinal safety led to an overall increase
in the use of NSAIDs. Using prescription claims data, a
Canadian study observed that the overall number of
NSAID prescriptions among patients aged over 65 years
increased by 68% between March and November 2000
following the introduction of celecoxib and rofecoxib. This
increase was almost entirely attributable to COX-2-
selective agents as the level of nsNSAID prescribing
remained relatively stable [25].
Following the withdrawal of rofecoxib and valdecoxib
in the mid-2000s, there was a reduction in prescribing of all
NSAIDs, primarily driven by marked decreases in the use
of COX-2-selective agents that were not compensated by
increases in nsNSAID use of the same magnitude. A pro-
spective cohortstudyusingAmericanregistrydatafoundthat
the use of COX-2-selective agents decreased from 55.1 to
29.2% among patients with RA or psoriatic arthritis between
2003 and 2005. In contrast, use of nsNSAIDs increased
from 50.2 to 73.9% [12]. Similarly, in Germany, COX-2-
selective agent prescriptions decreased by 37.1 million
deﬁned daily doses (DDDs) between 2004 and 2005, and
nsNSAID prescriptions increased by 19.0 million DDDs [13].
This study reported an overall decrease in NSAID use of
8.4% [13]. It could be speculated that availability of generic
COX-2-selective inhibitors in coming years following patent
expiration will result in a resurgence in their use, although this
remains to be seen.
Use of NSAIDs by patients
Use of NSAIDs, and in particular chronic use, increases
with age, with an estimated 10–40% of people aged over
65 years using prescribed or OTC NSAIDs daily [26, 27].
In a survey of patients aged over 55 years with knee OA in
two general practices in the UK, NSAIDs were used more
commonly among patients from an afﬂuent rural area
compared with those from a deprived urban area [28].
There is also evidence to suggest that many patients use
NSAIDs intermittently, as less than half receive prescrip-
tions with enough medication to sustain longer-term daily
use [29].
Use of OTC NSAIDs, generally available without pre-
scription at lower doses, is also very common. A USA poll
of more than 2,000 adults found that approximately 30%
use OTC analgesics on a regular basis for arthritis or some
other form of chronic pain [30]. Based on the ﬁndings of
the 1997 Roper survey commissioned by the American
Gastroenterological Association and the 2002 National
Consumer League study, with a combined total of 9,062
respondents, ibuprofen-based NSAIDs are the most widely
used OTC NSAIDs, with the majority of patients using
them on an as-needed basis [31]. The Roper study found
that among prescription NSAID users, approximately 40%
also use OTC NSAIDs at the same time [31].
Approximately one half of NSAID users in the Roper
survey were not aware of the potential side effects. Among
all NSAID users, 33% perceived prescription NSAIDs to
be safer and 32% perceived OTC NSAIDs to be safer.
Consumption of more than the recommended dose was
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Fig. 1 Proportion of global sales for NSAIDs [24]. Adapted by
permission from IMS Health, copyright 2008
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123more common among OTC NSAID users (26%) than
prescription NSAID users (8%) [31].
Comparative analgesic efﬁcacy of NSAIDs
NSAIDs have demonstrated short-term efﬁcacy compared
with placebo in the treatment of OA [3] (Fig. 2). The
efﬁcacy of NSAIDs has been further evaluated in a com-
parative effectiveness review for the Agency for Health-
care Research and Quality (AHRQ) Effective Healthcare
Program [32], a drug effectiveness review project by the
Oregon Health and Science University (OHSU), funded by
the Center for Evidence-based Policy [33] and a UK
National Health Service (NHS) health technology assess-
ment [34].
Comparisons and meta-analyses of published studies
have found that there are no clear differences in efﬁcacy
among nsNSAIDs at standard doses in the treatment of
knee, back, or hip pain [32, 33]. Similarly, based on more
than 20 randomized controlled trials and systematic
reviews, the AHRQ review found that there are no signif-
icant differences in efﬁcacy between COX-2-selective
agents and nsNSAIDs [32]. In a review of previous sys-
tematic reviews of randomized controlled trials, the NHS
health technology assessment found that COX-2-selective
agents had equivalent efﬁcacy to nsNSAIDs for the treat-
ment of RA and OA [34]. Although sometimes based on
data using supratherapeutic doses, celecoxib 200–800 mg/
day has efﬁcacy equivalent to naproxen 1,000 mg/day,
diclofenac 100–150 mg/day, and ibuprofen 2,400 mg/day.
Etoricoxib 60–120 mg/day also has efﬁcacy similar to
naproxen 1,000 mg/day, diclofenac 150 mg/day, and ibu-
profen 2,400 mg/day [34].
In randomized trials, celecoxib and nsNSAIDs have
been found to be associated with similar levels of pain
reduction in patients with OA, ankylosing spondylitis, and
RA [33]. In the Successive Celecoxib Efﬁcacy and Safety
Study (SUCCESS), celecoxib 200–400 mg/day was found
to have efﬁcacy comparable to naproxen 1,000 mg/day and
diclofenac 100 mg/day for the treatment of more than
13,000 patients with OA over 12 weeks [35].
The efﬁcacy of etoricoxib and nsNSAIDs has also been
compared in seven relatively small studies [34]. These
studies found that etoricoxib 30–120 mg/day had compa-
rable efﬁcacy to naproxen, diclofenac, and ibuprofen at
standard doses in patients with OA and RA [36–42]. In a
more recent long-term study, etoricoxib 90–120 mg/day
was found to have greater efﬁcacy compared with
naproxen 1,000 mg/day over 12 weeks, but similar efﬁcacy
over 121 weeks [43].
AmongCOX-2-selectiveagents,theefﬁcacyofrofecoxib
25 mg/day, etoricoxib 30 mg/day, and lumiracoxib 200 or
400 mg/day has been compared with celecoxib 200 mg/day.
No signiﬁcant differences for pain relief at these doses have
been found [32, 44, 45].
Number of patients P-value
-2 -1 0 -1 -2
Favors placebo Favors NSAID
Celecoxib
Acetaminophen
Etodolac/naproxen
Rofecoxib
Naproxen/nabumetone
Etoricoxib
Valdecoxib/naproxen
Meloxicam
Nabumetone
Celecoxib/diclofenac
Etodolac/nabumetone
Lumiracoxib
Flurbiprofen
Nabumetone
Celecoxib
Etodolac
Celecoxib
Combined
800
53
254
219
279
386
613
271
347
600
270
1,702
39
328
104
715
801
10,845
0.006
0.002
0.006
<0.001
0.733
<0.001
0.002
0.034
0.080
<0.001
0.002
0.003
0.119
0.351
0.053
0.015
<0.001
<0.001
Fig. 2 Efﬁcacy of NSAIDs
compared with placebo for the
treatment of OA of the knee [3].
Knee OA studies 2–13 weeks in
length. Adapted by permission
from BMJ Publishing Group
Limited (Bjordal JM et al. BMJ;
329: 1317, copyright 2004)
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123How effective are NSAIDs in clinical practice?
The majority of clinical trials evaluating the analgesic
efﬁcacy of NSAIDs typically report outcomes as mean
population changes. Such results can be difﬁcult to trans-
late for individual patients in clinical practice. In a recent
study, data from seven randomized, controlled OA trials
(C6 weeks’ duration) assessing the efﬁcacy of etoricoxib
compared with other NSAIDs or placebo, using the Wes-
tern Ontario and McMaster Universities Osteoarthritis
Index (WOMAC), investigated this NSAID’s effects on
different levels of pain relief [46]. While 60–80% of
patients experienced minimal pain relief (C15% improve-
ment from baseline), only 20–30% experienced extensive
pain relief (C70% improvement from baseline).
Comparative toxicity of NSAIDs
Like many drugs, NSAIDs are associated with a broad
range of side effects, including renal toxicity, exacerbation
of hypertension, ﬂuid retention, gastrointestinal complica-
tions, and cardiovascular events [15]. Furthermore, the
presence of chronic co-morbidities in many, particularly
elderly, patients with arthritis who require NSAIDs can be
associated with increased risks of complications resulting
in complex treatment decisions to balance risks and bene-
ﬁts [47].
Gastrointestinal toxicity
NSAIDs are associated with a spectrum of upper gastro-
intestinal complications, ranging from endoscopic ulcers in
10–30% of patients, to serious ulcer complications in 1–2%
of patients [48, 49], although the exact incidence is
changing [50]. In recent years, the effect of NSAIDs on the
lower gastrointestinal tract has begun to receive greater
attention with opinion moving toward a focus on the
complications affecting the whole gastrointestinal tract. At
present, lower gastrointestinal complications are less well
characterized but thought to be increasingly common [50–
52]. One systematic review reported the overall risk (OR)
of lower gastrointestinal bleeding to be 1.9–18.4 in case–
control studies [53].
In 1998, it was estimated that approximately 100,000
people were hospitalized annually in the USA as a result of
NSAID-related gastrointestinal complications [54], and
mortality is reported as approximately 5% [55], which
highlights the clinical importance of such events. Perhaps
more importantly for people with arthritis who have few
analgesic options, minor side effects (including symptoms
of dyspepsia) occur in up to 60% of patients [49] and poor
tolerability results in many patients discontinuing therapy
[56]. Management of gastrointestinal complications and
dyspepsia adds signiﬁcantly to the economic burden of
arthritis [57].
A nested case–control study found that, compared with
non-use, nsNSAIDs increased the risk of developing seri-
ous upper gastrointestinal complications by a factor of 3.7
(95% conﬁdence interval [CI] 3.1, 4.3), and COX-2-
selective agents by a factor of 2.6 (95% CI 1.9, 3.6) [9].
Among individual NSAIDs, the relative risk (RR) of
developing serious upper gastrointestinal complications
compared with non-use ranged from 2.0 with ibuprofen to
12.0 with etoricoxib, though this was based on retrospec-
tive analyses that probably had an element of confounding
by indication for the COX-2-selective agents. It has pre-
viously been reported that, based on meta-analyses from
1991 to 2004, the RR of serious gastrointestinal compli-
cations is 3–4-fold higher in nsNSAID users compared
with non-users [58]. A more recent systematic review of
observational studies reported that the RR for upper gas-
trointestinal bleeding or perforation varies between indi-
vidual NSAIDs, ranging from 1.42 (95% CI 0.85, 2.37)
with celecoxib to 14.54 (95% CI 5.87, 36.04) with ketor-
olac (Fig. 3), and is inﬂuenced by NSAID half-life [59].
The majority of studies evaluating the gastrointestinal
safety of NSAIDs have found that COX-2-selective
inhibitors are associated with a lower risk of ulcers and
complications than nsNSAIDs [35, 60–63]. However, in
some studies, the difference in rate of all upper gastroin-
testinal clinical events and complicated events is not sig-
niﬁcant [61, 63]. A 2008 review of randomized controlled
trials and meta-analyses estimated that COX-2-selective
agents are associated with 61% RR reduction for ulcer
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Fig. 3 Risk of upper gastrointestinal bleeding/perforation with
individual NSAIDs from published studies since 1990 [59].
aStudies
published after 2000. P-values derived from heterogeneity test and
n (number of studies). Adapted by permission from John Wiley &
Sons, Inc (Masso ´ Gonza ´lez EL et al. Arthritis Rheum; 62: 1592,
copyright 2010)
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123complications compared with nsNSAIDs [64] and a sepa-
rate systematic review of observational studies calculated
that the RR for upper gastrointestinal bleeding or perfora-
tion was greater with nsNSAIDs (RR 4.50; 95% CI 3.82,
5.31) than COX-2-selective agents (RR 1.88; 95% CI 0.96,
3.71) as a class, though it was noted that risk varied
between individual NSAIDs [59].
There are a number of risk factors for NSAID-associated
gastrointestinal injury, including high NSAID dose, older
age, Helicobacter pylori infection, a history of ulcer or
ulcer complications, and concomitant use of OTC NSAIDs,
low-dose aspirin, anticoagulants, or corticosteroids [65–
67]. Concomitant use of low-dose aspirin for cardiovas-
cular prophylaxis is common among NSAID users
(approximately 20–25% in clinical trials [62, 63, 68]) but
increases the risk for mucosal damage [69, 70] and elimi-
nates the gastrointestinal beneﬁts of COX-2-selective
agents [9, 62, 63]. For example, in a nested case–control
study, Garcı ´a Rodrı ´guez and Barreales Tolosa found that
the RR of upper gastrointestinal complications was higher
among patients using aspirin plus COX-2-selective agents
(RR 1.9; 95% CI 1.0, 3.6) compared with COX-2-selective
agents alone (RR 0.6; 95% CI 0.4, 0.9) [9].
NSAIDs, particularly diclofenac, nimesulide, and sul-
indac, are also associated with drug-related hepatotoxic-
ity, as indicated by liver function test abnormalities in
clinical trials and reports of fatal liver injury among
NSAID users [71, 72]. Lumiracoxib, an analog of dic-
lofenac, is a COX-2-selective inhibitor that was never
approved in the USA and was withdrawn from the European
market in 2007 as a result of concerns about potential liver
toxicity [73].
Cardiovascular toxicity
NSAIDs are associated with an increased risk of cardio-
vascular adverse events such as myocardial infarction,
heart failure, and hypertension [74], and this increase in
risk appears to be dependent on duration of exposure [33].
It has been suggested that the mechanism for this may be
the impact of COX inhibition on the balance between
COX-2-mediated production of pro-aggregatory throm-
boxane in platelets and anti-aggregatory prostaglandin I2 in
endothelial cells [18, 75, 76].
Previously, increasing COX-1 selectivity has been
associated with an increased risk of gastrointestinal toxic-
ity, while increasing COX-2 selectivity has been associated
with an increased risk of cardiovascular toxicity [77]. It has
since been suggested that this concept is ﬂawed, as while
COX-2-selective agents have varying but little effect on
COX-1, COX-2-selective agents and nsNSAIDs both
inhibit COX-2 at traditional therapeutic doses and have
potential for cardiovascular toxicity. Therefore, COX
selectivity alone is not sufﬁcient to deﬁne the risk of
NSAID-associated complications. Based on clinical evi-
dence and an increased understanding of differences
between individual NSAIDs, an alternative concept has
been proposed that incorporates the association between
increasing dose and NSAID-associated gastrointestinal and
cardiovascular risk [77].
COX-2-selective agents
A meta-analysis comparing the effects of different COX-2-
selective agents found that there was a signiﬁcant increase
in the incidence of serious vascular events with COX-2-
selective agents compared with placebo (rate ratio 1.42;
95% CI 1.13, 1.78; P = 0.003) that was primarily as a
result of increased risk of myocardial infarction [78].
In the Vioxx Gastrointestinal Outcomes Research
(VIGOR) study, it was observed that rofecoxib 50 mg/day
was associated with a fourfold increase in the incidence of
myocardial infarction compared with naproxen 1,000 mg/
day in patients with RA [60]. The Adenomatous Polyp
Prevention On Vioxx (APPROVe) study found that rofecoxib
25 mg/day was associated with an increased RR of
thrombotic events compared with placebo in patients with a
history of colorectal adenomas after 18 months of treat-
ment and an increased risk of myocardial infarction after
15 months of treatment [79]. Based on these ﬁndings,
rofecoxib was withdrawn from the market in 2004. Val-
decoxib was subsequently withdrawn in 2005 [80].
Cardiovascular safety data for celecoxib are available
from three long-term trials: the Alzheimer’s Disease Anti-
inﬂammatory Prevention Trial (ADAPT) [81], the Ade-
noma Prevention with Celecoxib (APC) study [82], and the
Prevention of colorectal Sporadic Adenomatous Polyps
(PreSAP) study [83]. Celecoxib 200–400 mg/day was
associated with a signiﬁcant and dose-related increase in
death from cardiovascular causes in APC, but not in Pre-
SAP or ADAPT [84]. However, based on an analysis of
cardiovascular events in APC, all three studies were sub-
sequently suspended [84]. In one systematic review, cele-
coxib was associated with a greater risk of myocardial
infarction compared with placebo and nsNSAIDs [34], but
another two concluded that the cardiovascular risk of
celecoxib is generally similar to that with placebo or
nsNSAIDs [84, 85].
The cardiovascular safety of etoricoxib 60 or 90 mg/day
was compared with diclofenac 150 mg/day in a pooled
analysis of data from three trials in the Multinational
Etoricoxib and Diclofenac Arthritis Long-term (MEDAL)
program.Therisk forthromboticcardiovascular eventswith
long-term therapy was found to be similar to nsNSAID
treatment (hazard ratio 0.95; 95% CI 0.81, 1.11) [86].
1496 Rheumatol Int (2012) 32:1491–1502
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The cardiovascular safety of nsNSAIDs has been a highly
contentious issue during the latter half of the last decade. A
meta-analysis of randomized trials found that high-dose
ibuprofen (rate ratio 1.51; 95% CI 0.96, 2.37) and high-
dose diclofenac (rate ratio 1.63; 95% CI 1.12, 2.37) were
associated with a moderately increased risk of any vascular
events compared with placebo, similar to that observed
with COX-2-selective agents, but the risks associated with
naproxen, though they cannot be completely excluded,
were substantially lower (rate ratio 0.92; 95% CI 0.67,
1.26) (Fig. 4)[ 78]. Another systematic review and meta-
analysis of controlled observational studies comparing the
risks of cardiovascular events with individual NSAIDs
found that diclofenac was associated with a higher risk of
cardiovascular events (RR 1.40; 95% CI 1.16, 1.70) than
ibuprofen (RR 1.07; 95% CI 0.97, 1.18) and naproxen (RR
0.97; 95% CI 0.87, 1.07) [87]. This issue has been further
complicated by evidence from pharmacokinetic studies
suggesting an interaction between ibuprofen and aspirin
that results in reduced platelet inhibition by aspirin [88].
However, overall, there is a lack of long-term studies that
have evaluated both gastrointestinal and cardiovascular
events, particularly for nsNSAIDs, which may limit
our understanding of the true beneﬁts and risks of
NSAIDs [33].
Modern recommendations aimed at reducing NSAID
toxicity
It is important that both individual NSAID and patient risk
factors should be considered in prescribing decisions.
Current treatment guidelines recommend that NSAIDs
should be used at their lowest effective dose [5, 6, 89] and
that long-term use should be avoided where possible [6, 7].
Reducing gastrointestinal risk
It is generally recommended that patients with gastroin-
testinal risk factors should be treated with COX-2-selective
agents or nsNSAIDs plus gastroprotective co-therapy
[5–7, 90, 91]. Available gastroprotective agents include
H2 receptor antagonists, misoprostol, and proton pump
inhibitors (PPIs). PPIs have superior efﬁcacy to H2 receptor
antagonists [92, 93], which do not provide sufﬁcient acid
suppression at traditional doses to prevent most ulcers [94–
96]. Compared with misoprostol, PPIs have not demon-
strated superior efﬁcacy in ulcer prevention, but they are
deemed to be clinically equivalent when the safety and
poor compliance issues of misoprostol are considered [97].
While it should be remembered that PPIs may not pro-
tect the lower gastrointestinal tract [47], a USA cohort
study investigating ulcer-related hospitalizations found that
the treatment with an nsNSAID plus a PPI was at least as
effective as treatment with a COX-2-selective agent. The
risk of hospitalization was reduced by 54% in patients
using either NSAIDs plus PPI co-therapy or COX-2-
selective agents compared with NSAIDs alone [98]. A
recent study compared the effects of treatment with cele-
coxib or diclofenac plus omeprazole for 6 months on
gastrointestinal outcomes in patients with OA or RA.
While no difference in incidence of hemorrhage, obstruc-
tion, or perforation between treatments was observed, a
lower incidence of anemia (C20 g/L decrease in hemo-
globin or C10% decrease in hematocrit; with or without
deﬁned gastrointestinal origin) was reported with COX-2-
selective agent treatment compared with NSAID plus
PPI [51].
A more recent concept is that of further reducing gas-
trointestinal risk by combining a COX-2-selective agent
with a PPI, an approach that has been recommended in the
UK based on national-level cost-effectiveness analyses [7,
99]. It has been demonstrated that addition of a PPI to
treatment with a COX-2-selective agent signiﬁcantly
reduces the absolute risk of endoscopic gastric ulcers
compared with placebo [100].
Although PPIs are generally considered to be well tol-
erated, the potential for adverse events or interactions with
other therapies should be a factor in clinical decision
making. For example, in a recent retrospective study, PPI
therapy was associated with an increased risk of adverse
cardiovascular events in aspirin-treated patients surviving
30 days after a ﬁrst myocardial infarction, although this
would be a population in which NSAID use would be
avoided [101].
42 (a) Naproxen
No. of trials COX-2 inhibitor versus:
Heterogeneity between (a) and (b): P = 0.001; between non-naproxen NSAIDs: P = 0.3
24
26
7
51
91
Ibuprofen
Diclofenac
Other non-naproxen
(b) Any non-naproxen
Any NSAID
0.88 (0.69, 1.12)
P = 0.3
1.16 (0.97, 1.38)
P = 0.1
1.57 (1.21, 2.03)
P = 0.0006
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Fig. 4 Risk of vascular events with COX-2-selective agents versus
nsNSAIDs [78]. Adapted by permission from BMJ Publishing Group
Limited (Kearney PM et al. BMJ; 332: 1302, copyright 2006)
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observational studies suggests that as many as 60–80% of
patients using NSAIDs who have gastrointestinal risk
factors, including those using concomitant low-dose aspi-
rin, do not receive appropriate gastroprotection [102, 103].
In addition, of those patients who are prescribed gastro-
protective agents, more than 30% may be non-adherent,
which increases their risk of gastrointestinal events [100,
104, 105]. Fixed-dose combinations of NSAIDs and gas-
troprotective agents have emerged as a strategy to improve
adherence. For example, Arthrotec
 is a combination
product containing diclofenac sodium 50–75 mg plus
misoprostol 200 lg that is approved for the treatment of
osteoarthritis or rheumatoid arthritis in patients at high risk
of developing NSAID-associated ulcers and their compli-
cations [106, 107]. More recently, a ﬁxed-dose combina-
tion of naproxen 500 mg and esomeprazole magnesium
20 mg (VIMOVO
) has been approved for the relief of
signs and symptoms of OA, RA, and ankylosing spondy-
litis, and to decrease the risk of developing ulcers in
patients at risk for developing NSAID-associated gastric
ulcers [68, 108]. An additional combination therapy in
development for this patient population is ibuprofen
800 mg plus famotidine 26.6 mg (DUEXA
)[ 109].
Reducing cardiovascular risk
The American Heart Association recommends that all
NSAIDs should be used at their lowest effective dose.
These and other guidelines, including those from the
American College of Rheumatology, recommend that all
NSAIDs, and particularly COX-2-selective agents, should
be avoided where possible in patients with cardiovascular
risk factors (such as hypertension, hypercholesterolemia,
angina, edema, recent bypass surgery, and a history of
myocardial infarction or other cardiovascular events), and
should be used only when sufﬁcient pain relief is not
achieved with other therapies and the beneﬁt outweighs the
increased cardiovascular risk [74, 89–91, 110]. Where
NSAID therapy is required for patients at risk of cardio-
vascular complications, naproxen is recommended as the
NSAID of choice [74, 89–91, 110].
Conclusions
The start of the last decade saw a large increase in the use
of NSAIDs following the introduction of COX-2-selective
agents, which demonstrated improved gastrointestinal tol-
erability relative to nsNSAIDs, but concerns about their
cardiovascular safety emerged and subsequently resulted in
reduced use and revised thinking on the classiﬁcation and
safety of all NSAIDs. It is now clear that all NSAIDs are
associated with varying degrees of cardiovascular and
gastrointestinal risk and that individual drug and patient
factors should be considered in treatment decisions.
Whilestrategiesexisttopreventcomplicationsinpatients
at risk of NSAID-associated gastrointestinal and cardiovas-
cularinjury,theyareoftenunderutilizedordifﬁculttoapply,
particularly in patients with both types of risk factor. There
remains a great need for data-driven algorithms combining
cardiovascular and gastrointestinal risk that can be applied
when assessing an individual patient’s risk.
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